Loading Conceptually similar LOXO ONCOLOGY-TESTING/ CDocument Date: April 03, 2018 Headline: Loxo Oncology's quick rise EPS CLoxo Oncology is awaiting U.S. approval of its drug, larotrectinib, that appears to be highly effective against a wide range of solid tumor cancers that share a rare genetic mutation. Select usage Category System ID: RTX5FQAB Fixture ID: ET1EE431L3I2D Size: 2067px × 1578px File Size: 868.53 KB Photographer: REUTERS GRAPHICSParent folder: 2018-04Related Images: View MoreAdd to lightboxAdd to cartBuy/download